Irene Gavras

List of Publications by Year in descending order

108 papers	4,602 citations	109321 35 h-index	102487 66 g-index
109 all docs	109 docs citations	109 times ranked	2186 citing authors

#	Article	IF	Citations
1	Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man. New England Journal of Medicine, 1978, 298, 991-995.	27.0	623
2	An Angiotensin Converting-Enzyme Inhibitor to Identify and Treat Vasoconstrictor and Volume Factors in Hypertensive Patients. New England Journal of Medicine, 1974, 291, 817-821.	27.0	350
3	The Î±2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. Journal of Hypertension, 2001, 19, 2115-2124.	0.5	231
4	Antihypertensive Therapy with MK 4211. Journal of Cardiovascular Pharmacology, 1982, 4, 966-972.	1.9	227
5	Volume factor in low and normal renin essential hypertension. American Journal of Cardiology, 1973, 32, 523-532.	1.6	192
6	ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".. Lancet, The, 1981, 318, 543-547.	13.7	182
7	Vasoactive Potential of the B1Bradykinin Receptor in Normotension and Hypertension. Circulation Research, 2001, 88, 275-281.	4.5	134
8	Models of Experimental Hypertension in Mice. Hypertension, 1996, 28, 1064-1069.	2.7	132
9	Reciprocal Relation between Renin Dependency and Sodium Dependency in Essential Hypertension. New England Journal of Medicine, 1976, 295, 1278-1283.	27.0	119
10	Bradykinin-mediated effects of ACE inhibition. Kidney International, 1992, 42, 1020-1029.	5.2	112
11	Role of the Î±2B-Adrenergic Receptor in the Development of Salt-Induced Hypertension. Hypertension, 1999, 33, 14-17.	2.7	105
12	Role of vasopressin in essential hypertension. Journal of Hypertension, 1997, 15, 545-550.	0.5	93
13	Role of the B2Receptor of Bradykinin in Insulin Sensitivity. Hypertension, 2001, 38, 1355-1360.	2.7	85
14	Evidence for Linkage Between Essential Hypertension and a Putative Locus on Human Chromosome 17. Hypertension, 1999, 34, 4-7.	2.7	81
15	Sympathoinhibitory Function of the Î±2A-Adrenergic Receptor Subtype. Hypertension, 1999, 34, 403-407.	2.7	75
16	Suppressing Sympathetic Activation in Congestive Heart Failure. Hypertension, 1995, 26, 719-724.	2.7	67
17	Pleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease. American Journal of Hypertension, 2008, 21, 1163-1168.	2.0	57
18	Fatal Pancytopenia Associated with the Use of Captopril. Annals of Internal Medicine, 1981, 94, 58.	3.9	56

#	Article	IF	Citations
19	Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. Brain Research, 1986, 381, 322-326.	2.2	49
20	Role of the postsynaptic Î±2-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. General Pharmacology, 2000, 34, 101-106.	0.7	49
21	Cardioprotective potential of angiotensin converting enzyme inhibitors. Journal of Hypertension, 1991, 9, 385-392.	0.5	45
22	Autosomal Dominant Orthostatic Hypotensive Disorder Maps to Chromosome 18q. American Journal of Human Genetics, 1998, 63, 1425-1430.	6.2	45
23	Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct. Hypertension, 2008, 51, 1352-1357.	2.7	44
24	Î±-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. Brain Research, 1985, 347, 372-375.	2.2	43
25	Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. Journal of Hypertension, 1989, 7, 601-606.	0.5	43
26	Fixed-Drug Combinations as First-Line Treatment for Hypertension. Progress in Cardiovascular Diseases, 2006, 48, 416-425.	3.1	43
27	Cardioprotective properties of bradykinin: role of the B2 receptor. Hypertension Research, 2010, 33, 772-777.	2.7	43
28	Cardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct. American Journal of Hypertension, 2010, 23, 562-568.	2.0	42
29	Enalaprilat in Hypertensive Emergencies. Journal of Clinical Pharmacology, 1986, 26, 39-43.	2.0	41
30	Role of Î± ₂ -Adrenergic Receptor Subtypes in the Acute Hypertensive Response to Hypertonic Saline Infusion in Anephric Mice. Hypertension, 2000, 35, 609-613.	2.7	41
31	Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E268-E274.	3.5	41
32	Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1778-H1783.	3.2	39
33	A new highly potent antagonist of bradykinin. Peptides, 1990, 11, 1041-1043.	2.4	37
34	Role of Bradykinin in Insulin Sensitivity and Blood Pressure Regulation During Hyperinsulinemia. Hypertension, 1995, 25, 1003-1007.	2.7	37
35	Prediction of sustained antihypertensive efficacy of chronic captopril therapy: Relationships to immediate blood pressure response and control plasma renin activity. American Heart Journal, 1982, 103, 384-390.	2.7	36
36	Effects of Antisense Oligodeoxynucleotide Targeting of the Î± _{2B} -Adrenergic Receptor Messenger RNA in the Central Nervous System. Hypertension, 2001, 38, 1075-1080.	2.7	36

#	Article	IF	Citations
37	Captopril and Enalapril. Annals of Internal Medicine, 1983, 98, 556.	3.9	35
38	Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update. Journal of Clinical Pharmacology, 1981, 21, 508-516.	2.0	34
39	Calcium Stimulates Vasopressin Release. Journal of Hypertension, 1986, 4, 451-454.	0.5	33
40	Effect of Angiotensin Converting Enzyme Inhibition on Blood Pressure, Plasma Renin Activity and Plasma Aldosterone in Essential Hypertension *. Journal of Clinical Endocrinology and Metabolism, 1978, 46, 220-226.	3.6	30
41	Mechanisms Mediating the Vasoactive Effects of the B ₁ Receptors of Bradykinin. Hypertension, 2003, 42, 1021-1025.	2.7	30
42	Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. American Journal of Hypertension, 2005, 18, 18-22.	2.0	30
43	Effect of Aging on Vasopressin, Catecholamines, and Alpha₂â€Adrenergic Receptors. Journal of the American Geriatrics Society, 1990, 38, 628-632.	2.6	28
44	Role of Î±2-adrenergic receptors in hypertension. American Journal of Hypertension, 2001, 14, S171-S177.	2.0	28
45	Angiotensin-converting enzyme regulates bradykinin receptor gene expression. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1814-H1820.	3.2	27
46	Role of Vasoconstrictor Systems in Experimental Glucocorticoid-Hypertension in Rats. Clinical Science, 1983, 65, 255-261.	4.3	26
47	Sodium Chloride-induced Partial Inhibition In Vivo Of Alpha2-Adrenoceptor Agonist Function. Journal of Hypertension, 1985, 3, 269-274.	0.5	26
48	Combination therapy as first-line treatment for hypertension. Current Hypertension Reports, 2004, 6, 267-272.	3.5	26
49	Role of Substance P in Blood Pressure Regulation in Salt-Dependent Experimental Hypertension. Hypertension, 1997, 29, 506-509.	2.7	24
50	â€˜Volume-expandedâ€™ hypertension. Journal of Hypertension, 2012, 30, 655-659.	0.5	24
51	Age-related changes of bradykinin B1 and B2 receptors in rat heart. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H202-H205.	3.2	23
52	A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension. Journal of Clinical Pharmacology, 1979, 19, 8-14.	2.0	21
53	Effects of a Novel Renin Inhibitor in Patients with Essential Hypertension. Journal of Cardiovascular Pharmacology, 1990, 15, 493-500.	1.9	21
54	A novel bradykinin antagonist with improved properties. Journal of Pharmacy and Pharmacology, 2011, 43, 887-888.	2.4	21

#	Article	IF	Citations
55	Studies on the Activity of the Sympathetic Nervous System in Essential Hypertension. Journal of Human Stress, 1978, 4, 22-28.	0.7	20
56	Role of Bradykinin in Hypertension and the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors. American Journal of the Medical Sciences, 1988, 295, 305-307.	1.1	19
57	Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. Journal of Hypertension, 1991, 9, 805-812.	0.5	19
58	Hypertensice response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Research, 1985, 343, 113-119.	2.2	18
59	Comparison of Spirapril, Isradipine, or Combination in Hypertensive Patients With Left Ventricular Hypertrophy Effects on LVH Regression and Arrhythmogenic Propensity. American Journal of Hypertension, 1998, 11, 640-648.	2.0	18
60	Central Î±2B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. Journal of Hypertension, 2003, 21, 961-967.	0.5	18
61	A Novel Gene (Cmya3) Induced in the Heart by Angiotensin II-Dependent but not Salt-Dependent Hypertension in Mice. American Journal of Hypertension, 2006, 19, 275-281.	2.0	17
62	Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure. Hypertension, 1997, 29, 525-530.	2.7	16
63	Chronic Sympathetic Suppression in the Treatment of Chronic Congestive Heart Failure. Clinical and Experimental Hypertension, 1998, 20, 717-731.	1.3	16
64	Effect of Nadolol in Treatment of Hypertension. Journal of Clinical Pharmacology, 1979, 19, 137-147.	2.0	15
65	Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. American Journal of Medicine, 1987, 83, 20-23.	1.5	15
66	Are Patients Who Develop Angioedema With ACE Inhibition at Risk of the Same Problem With AT1 Receptor Blockers?. Archives of Internal Medicine, 2003, 163, 240.	3.8	15
67	HYPOTENSIVE EFFECT OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR SQ 20,881. Lancet, The, 1974, 304, 353.	13.7	13
68	Central Alpha-Adrenoceptors During the Development of Hypertension in Rats on High and Low Salt Intake. Journal of Hypertension, 1986, 4, 719-726.	0.5	13
69	Augmentation of Coronary Blood Flow by Ace Inhibition: Role of Angiotensin and Bradykinin. Clinical and Experimental Hypertension, 1995, 17, 1059-1072.	1.3	13
70	Safety and Tolerability of Eprosartan. Pharmacotherapy, 1999, 19, 102S-107S.	2.6	13
71	Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 323-328.	0.6	13
72	Age and Race Determine Vasopressin Participation in Upright Blood Pressure Control in Essential Hypertension. Annals of the New York Academy of Sciences, 1993, 689, 534-536.	3.8	12

#	Article	IF	Citations
73	Blockade of platelet alpha2B-adrenergic receptors: A novel antiaggregant mechanism. International Journal of Cardiology, 2013, 168, 2561-2566.	1.7	12
74	Long-Term Inhibition of the Central Î±2B-Adrenergic Receptor Gene Via Recombinant AAV-Delivered Antisense in Hypertensive Rats. American Journal of Hypertension, 2006, 19, 1135-1143.	2.0	10
75	Salt-induced hypertension in chronic renal failure: Evidence for a neurogenic mechanism. Life Sciences, 1983, 32, 733-740.	4.3	9
76	Frequency of Coronary Artery Disease in Patients With Renal Artery Stenosis Without Clinical Manifestations of Coronary Insufficiency. American Journal of Hypertension, 2006, 19, 1125-1128.	2.0	9
77	Nifedipine in the Treatment of Essential Hypertension. Journal of Clinical Pharmacology, 1985, 25, 429-432.	2.0	8
78	Hypertension in Transgenic Mice With Brain-Selective Overexpression of the Â2B-Adrenoceptor. American Journal of Hypertension, 2009, 22, 41-45.	2.0	8
79	Hemodynamic and Humoral Correlates in Essential Hypertension. Hypertension, 1997, 30, 730-734.	2.7	8
80	Systemic and Regional Hemodynamic Effects of Propranolol in Intact and Anephric Rats. Clinical and Experimental Hypertension, 1983, 5, 729-739.	0.3	7
81	Central Catecholamines and Alpha-Adrenoceptors in Acute Hypertension Induced by Intracerebroventricular Hypertonic Saline. Journal of Hypertension, 1987, 5, 699-704.	0.5	7
82	Hypertension, vasoactive peptides and coagulation factors. Journal of Hypertension, 2004, 22, 1091-1092.	0.5	7
83	Evidence for Dopaminergic Regulation of Vasopressin Release in the Anephric Rat. Journal of Hypertension, 1984, 2, 311???316.	0.5	6
84	Clinical utility of angiotensin converting enzyme inhibitors in hypertension. American Journal of Medicine, 1986, 81, 28-31.	1.5	5
85	Cardioprotective potential of angiotensinâ€converting enzyme inhibitors. Clinical Cardiology, 1991, 14, 68-71.	1.8	5
86	Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 257.	1.5	5
87	Inhibition of the Î±1D-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascular Pharmacology, 2007, 46, 367-372.	2.1	5
88	Effect of Pindolol on Blood Pressure, Plasma Renin Activity, and Catecholamines in Hypertensive Patients. Journal of Clinical Pharmacology, 1981, 21, 79-83.	2.0	4
89	Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats. European Journal of Pharmacology, 1984, 102, 515-519.	3.5	4
90	Renin-angiotensin and vasopressin in the development of salt-induced hypertension. Journal of Hypertension, 1988, 6, 999-1002.	0.5	4

#	Article	IF	Citations
91	ACE Inhibitors: A Decade of Clinical Experience. Hospital Practice (1995), 1993, 28, 117-127.	1.0	4
92	Isradipine versus captopril in patients with essential hypertension. Clinical Therapeutics, 1995, 17, 648-654.	2.5	4
93	The Economics of Therapeutic Advances. Archives of Internal Medicine, 1999, 159, 2634.	3.8	4
94	The role of ACE inhibition in heart failure. , 2001, , 71-79.		4
95	Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. American Journal of Hypertension, 2002, 15, 42-47.	2.0	3
96	The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. American Journal of Hypertension, 2003, 16, 1000-1005.	2.0	3
97	The debate goes onâ€"What is your choice?. American Journal of Cardiology, 2005, 95, 53-54.	1.6	3
98	Angiotensin converting enzyme inhibitors. Journal of Hypertension, 1991, 9, 1075.	0.5	2
99	Modern Approaches to Initiating Antihypertensive Therapy. Cardiology Clinics, 1995, 13, 593-598.	2.2	2
100	Cardiovascular Effects of a Specific Nonpeptide Antagonist of Substance P (NK-1) Receptor in DOCA-Salt Hypertension. Hypertension, 1995, 26, 1186-1189.	2.7	2
101	Acute Effects of the New Angiotensinâ€Converting Enzyme Inhibitor Cilazapril: A Pilot Study. Journal of Clinical Pharmacology, 1988, 28, 660-663.	2.0	1
102	Renal artery clipping attenuates the progression of adriamycin nephropathy. American Journal of Hypertension, 1998, 11, 1124-1128.	2.0	1
103	Position Paper: Vasoconstriction and Volume Factors in Renovascular Hypertension. , 1981, , 159-164.		1
104	Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. Brain Research, 1987, 412, 182-184.	2.2	0
105	Is ancient Greek a dead language?. Lancet, The, 2001, 358, 424.	13.7	0
106	ACE Inhibitor Trials: Effects in Hypertension. , 2005, , 386-390.		0
107	The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension. , 1980, , 201-210.		0
108	The Renin-Angiotensin System and the Heart. , 1999, , 53-67.		0